Newsletter | November 25, 2025
FEATURED EDITORIAL
How Sethera Harnesses A Promiscuous Enzyme To Make Recombinant Peptides
A conversation with Karsten Eastman, Ph.D. and Vahe Bandarian, Ph.D., Sethera Therapeutics
A class of enzymes previously believed to be specific and intolerant of change might actually have broad applicability.
MOST POPULAR NEWS
•
Lunit & Labcorp To Advance AI-Powered Digital Pathology Research
LuminoDx Achieves CAP Accreditation
Parse Biosciences Announces FFPE-Compatible Barcoding Technology
PrognomiQ Launches ProVue Lung
BioNexus Gene Lab Corp. Announces Strategic Agreements With Fidelion Diagnostics
OCEAN Dx Rapid Diagnostic Test For Sepsis Matched Gold Standard
Azenta Launches Fully Networked 2D-Coded Tube Readers
Freenome Announces Exclusive Agreement With Roche
Abbott To Acquire Exact Sciences
Augurex Life Sciences Corp. Announces The Launch Of The 14-3-3eta Test For RA Diagnosis
Trinity Biotech Announces Collaboration To Advance Epigenetic Analysis
